Issue 18

The Enduring Attraction of Oral Solid Dose

Why not sign up for our future email newsletters? Sign up here.

Included in this issue:

LEAD STORY

Key Insights from CDMO Trends in Oral Solid Dosage

The first pills date back to roughly 1,500 BC, and whilst the pharmaceutical landscape continues to evolve, drug delivery via oral solid dosage (OSD) remains a dominant form due to the ease with which tablets are administered, patients’ familiarity with the dose form, and efficient manufacturing techniques. Even as other drug types - such as biologics - gain traction, OSD continues to be the standout performer in terms of cost-effectiveness, simple production processes, and enhanced long-term drug stability.

Read more here.

FEATURED STORIES

Biotech Financing: The Dynamics of Strategic Investment

Read more here.

CoreRx, Societal CDMO, and Bend Bioscience Merge Under Bend Bioscience Brand

Read more here.

Serán More Than Doubles US Clinical Manufacturing Capacity

Read more here.

Tanvex BioPharma and Bora Pharmaceuticals Forge Global Biologics Manufacturing Alliance

Read more here.

Superluminal Secures $120 Million to Boost GPCR Drug Discovery

Read more here.

Lotte Group Restructures Bio Division, Focuses on CDMO Growth

Read more here.

Eli Lilly Expands AI Horizons with Genetic Leap Partnership

Read more here.

UK to Ban More Dangerous Drugs

Read more here.

Lonza Expands Microbial Manufacturing to Meet Biotech Demand

Read more here.

Amgen's MariTide to Face Phase 3 Trials in Targetting Liver and Kidney Diseases

Read more here.

Bayer Launches Healthy Aging Ecosystem for Consumers

Read more here.

Lilly and Haya Join Forces for Breakthrough Metabolic Treatments

Read more here.

eGenesis Secures $191 Million for Pig Kidney Transplants

Read more here.